Week in Review, July 15–19

Bias in preclinical research; medical marijuana for kids; a swath of microbial genomes; plastic ocean habitats; rethinking scientific evaluation

Written byJef Akst
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

WIKIMEDIA, RAYSONHOJust as there is a tendency for researchers to publish positive results from clinical trials—relegating negative or neutral results languish to literature limbo—so too is there a bias towards successful preclinical studies in the literature, according to new research. This reporting bias could be one reason for the high failure rate of drugs once they enter clinical trials. The US Food and Drug Administration might reconsider many of the therapies that it’s cleared for human testing if the agency had access to the full suite of data on the drug.

“It’s really important [work] in that it gives another explanation for why treatments that appear to work in animals don’t work in humans,” David Torgerson, director of the York Trials Unit at the University of York in the U.K., told The Scientist. “I’ve personally always thought that animal models are potentially not as good as people might assume, but actually that view could be completely wrong, according to this paper.”

WIKIMEDIA, LAURIE AVOCADOIn 18 states and the District of Columbia, the use medical marijuana is legal for qualifying patients. All but 2 of these jurisdictions have OKed the drug for children. But controversy lingers over the drug’s use in minors, and even in places where children can obtain medical marijuana legally, regulatory hurdles can stand between a young patient and relief. That could be changing, however, reported Aimee Swartz this week. Just last month, the New Jersey Legislature passed a bill that, if signed into law by Governor Chris Christie, would put the level of regulatory burden for kids whose doctors have recommended medical cannabis on par with the requirements for adults, as well as legalize ingestible forms of the drug, such as lozenges, which are easier for children to take. “People want access to natural and safer remedies—for themselves and for their children,” said Paul Armentano, deputy of NORML, a non-profit organization that lobbies for the reform of prohibitive marijuana laws.

Of course, many questions remain regarding medical marijuana’s effects on children’s still-developing brains and nervous systems, and not all doctors endorse its use. But those who have prescribed it to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies